Objective To evaluate the efficacy of metformin on the level of interleukin-6 and tumor necrosis factor-αof impaired glucose tolerance patients with non-alcoholic fatty liver disease .Method 160 impaired glucose tolerance patients with non-alcoholic fatty liver disease were firstly divided into an experimental group (n=90) and a control group(n=70). On the basis of strict diet control and physical exercise , the experimental group was given metformin 1500 mg per day for a period of 24 weeks.The control group was treated with polyene phosphatidylcholine capsules 456mg per day also for a period of 24 weeks.Results After 24 weeks of treatment, the level of body mass index (BMI), anine aminotrans-ferase (ALT), fasting blood glucose (FPG), insulin, homeostasis model assessment-insulin resistance (HOMA IR) of the experimental group decreased more significantly than those of the control group (P<0.05).The difference between the two groups in the level of aspartate transaminase (AST) was not statistically significant (P >0.05).Conclusion The metformin treatment could improve the glucose metabolism indexes and insulin resistance of impaired glucose tolerance patients with non-alcoholic fatty liver disease , reduce liver enzyme and inflammatory cytokines , improve liver function , and lessen the degree of inflammation in liver .%目的：观察二甲双胍对糖耐量异常非酒精性脂肪性肝病（ nonalcoholic fatty liver disease ， NAFLD）患者IL-6、TNF-α的影响。方法将160例糖耐量异常NAFLD患者随机分为观察组（ n＝90）和对照组（ n＝70）。在严格控制饮食和运动的基础上，观察组加用二甲双胍1500 mg／d，对照组加用多烯磷脂酰胆碱胶囊456 mg／d，均治疗24周。结果治疗24周后，与对照组比较，观察疗组患者BMI、ALT、FPG、insulin、HOMA-IR、hs-CRP、TNF-α和IL-6水平均显著降低（P＜0．05）；两组间AST水平差异无统计学意义（P＞0．05）。结论二甲双胍能改善糖耐量异常NAFLD患者糖代谢指标和胰岛素抵抗，降低肝酶和炎症细胞因子水平。
展开▼
